Chimerix is developing vitally important new antiviral medicines for the treatment of life-threatening diseases. Led by a world-class team of antiviral experts and pharmaceutical drug developers, we are advancing a rich portfolio of clinical- and early-stage therapeutics to address serious viruses including cytomegalovirus (CMV), smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza.